These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16669341)

  • 41. [The mixing of powders].
    Kata M; Kedvessy G
    Acta Pharm Hung; 1971 Nov; 41(6):259-66. PubMed ID: 5139162
    [No Abstract]   [Full Text] [Related]  

  • 42. Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, Md.
    Shah VP; Flynn GL; Yacobi A; Maibach HI; Bon C; Fleischer NM; Franz TJ; Kaplan SA; Kawamoto J; Lesko LJ; Marty JP; Pershing LK; Schaefer H; Sequeira JA; Shrivastava SP; Wilkin J; Williams RL
    Skin Pharmacol Appl Skin Physiol; 1998; 11(2):117-24. PubMed ID: 9603663
    [No Abstract]   [Full Text] [Related]  

  • 43. Nanoscopic friction behavior of pharmaceutical materials.
    Lee J
    Int J Pharm; 2007 Aug; 340(1-2):191-7. PubMed ID: 17442509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mixing in process vessels used in biopharmaceutical manufacturing.
    Ram K; Vickroy TB; Lamb KA; Slater NK; Dennis JS; Duffy LE
    Biotechnol Prog; 2000; 16(2):244-7. PubMed ID: 10753450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Czechoslovakian mass-produced external dermatologic agents and trends in their development during the past 30 years].
    Melichar M
    Cesk Farm; 1984 Dec; 33(10):433-9. PubMed ID: 6397254
    [No Abstract]   [Full Text] [Related]  

  • 46. [The drug. Composition, Galenic forms and ways of administration].
    Hémidy PY; Woronoff-Lemsi MC
    Soins; 1998; (622):49-50. PubMed ID: 9574074
    [No Abstract]   [Full Text] [Related]  

  • 47. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leveraging elevated temperature and particle size reduction to extract API from various tablet formulations.
    Nickerson B; Arikpo WB; Berry MR; Bobin VJ; Houck TL; Mansour HL; Warzeka J
    J Pharm Biomed Anal; 2008 Jun; 47(2):268-78. PubMed ID: 18280688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The manufacture of sterile topical products.
    Longworth AR
    Bull Parenter Drug Assoc; 1975; 29(5):238-49. PubMed ID: 1182334
    [No Abstract]   [Full Text] [Related]  

  • 50. Validation study of the unguator, an apparatus for compounding dermatological preparations.
    Piette M; Stassen T; Kinget R; Delattre L
    Int J Pharm Compd; 2006; 10(6):469-77. PubMed ID: 23974421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meeting commentary--formulating better medicines for children.
    Hempenstall J; Tuleu C
    Int J Pharm; 2009 Sep; 379(1):143-5. PubMed ID: 19576979
    [No Abstract]   [Full Text] [Related]  

  • 52. Current perspectives in dissolution testing of conventional and novel dosage forms.
    Azarmi S; Roa W; Löbenberg R
    Int J Pharm; 2007 Jan; 328(1):12-21. PubMed ID: 17084051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug compounding position statement adopted.
    J Am Vet Med Assoc; 2001 Jan; 218(2):173. PubMed ID: 11195806
    [No Abstract]   [Full Text] [Related]  

  • 54. Medication advice.
    Solo L
    Aust Nurs J; 2005 Oct; 13(4):3. PubMed ID: 16496822
    [No Abstract]   [Full Text] [Related]  

  • 55. [A new approach for preparing gels containing NSAIDs].
    Kinget R
    J Pharm Belg; 2008 Mar; 63(1):1-3. PubMed ID: 18479074
    [No Abstract]   [Full Text] [Related]  

  • 56. The presence of microorganisms in some common excipients used in tablet formulation.
    Obuekwe IF; Eichie F
    Acta Pol Pharm; 2006; 63(2):121-5. PubMed ID: 17514875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Near infrared spectroscopy in the development of solid dosage forms.
    Räsänen E; Sandler N
    J Pharm Pharmacol; 2007 Feb; 59(2):147-59. PubMed ID: 17270069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The rate of solubility in fixed dosage forms for oral use. I].
    Polderman J; de Blaey CJ; Weekers-Andersen AB
    Pharm Weekbl; 1972 Sep; 22(38):601-10 contd. PubMed ID: 4640607
    [No Abstract]   [Full Text] [Related]  

  • 59. [The rate of solubility in fixed dosage forms for oral use. II].
    Polderman J; de Blaey CJ; Weekers-Andersen AB
    Pharm Weekbl; 1972 Sep; 107(39):613-23 contd. PubMed ID: 4641988
    [No Abstract]   [Full Text] [Related]  

  • 60. [Preparation of some complex drug forms].
    Iampol'skaia MM; Ponomarenko GF
    Farm Zh; 1969; 24(2):81-2. PubMed ID: 5793397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.